BBIO oral infigratinib shows benefits in PROPEL 3 phase 3
TradeXchange says BBIO’s oral infigratinib showed meaningful benefits within 52 weeks in children with achondroplasia in the Phase 3 PROPEL 3 trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.